Reed Benson Biography and Net Worth

General Counsel of Co-Diagnostics


Reed L Benson serves as Chief Financial Officer, Secretary of the Company. He has been Chief Financial Officer and Secretary from November 2014 to the present and a director from November 2014 to May 2017. Since September, 2008 to the present, in addition to the private practice of law, he is a founder and partner of Legends Capital Group, LLC, a privately held venture capital group that identifies investment opportunities in natural resources, bio tech and technology fields. From October 2004 to September 2008 he was employed as Chief Financial Officer, Secretary, and General Counsel and member of Board of Directors of Broadcast International, Inc., a publicly traded communications services company. From 2001 to October 2004, he was in the private practice of law where his practice focused on tax and business related matters. From July 1995 to January 2001 he was secretary and general counsel for Data Broadcasting Corporation, a provider of market information to individual investors. Mr. Benson received his J.D. degree from the University of Utah School of Law in 1976 and a Bachelor of Science Degree in Accounting from the University of Utah in 1971. Mr. Benson became a Certified Public Accountant in 1974. Mr. Benson’s experience in finance, accounting and business consulting, together with his role as our CFO and prior public company directorship, provide Mr. Benson with expertise enabling critical input to our company.

What is Reed L. Benson's net worth?

The estimated net worth of Reed L. Benson is at least $1.14 as of May 19th, 2021. Mr. Benson owns 1 shares of Co-Diagnostics stock worth more than $1 as of April 25th. This net worth evaluation does not reflect any other assets that Mr. Benson may own. Learn More about Reed L. Benson's net worth.

How do I contact Reed L. Benson?

The corporate mailing address for Mr. Benson and other Co-Diagnostics executives is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. Co-Diagnostics can also be reached via phone at (801) 438-1036 and via email at [email protected]. Learn More on Reed L. Benson's contact information.

Has Reed L. Benson been buying or selling shares of Co-Diagnostics?

Reed L. Benson has not been actively trading shares of Co-Diagnostics in the last ninety days. Most recently, Reed L. Benson sold 108,334 shares of the business's stock in a transaction on Wednesday, May 19th. The shares were sold at an average price of $8.53, for a transaction totalling $924,089.02. Following the completion of the sale, the general counsel now directly owns 1 shares of the company's stock, valued at $8.53. Learn More on Reed L. Benson's trading history.

Who are Co-Diagnostics' active insiders?

Co-Diagnostics' insider roster includes Reed Benson (General Counsel), and Eugene Durenard (Director). Learn More on Co-Diagnostics' active insiders.

Reed L. Benson Insider Trading History at Co-Diagnostics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/19/2021Sell108,334$8.53$924,089.021View SEC Filing Icon  
11/25/2020Sell89,524$10.50$940,002.00100,000View SEC Filing Icon  
See Full Table

Reed L. Benson Buying and Selling Activity at Co-Diagnostics

This chart shows Reed L Benson's buying and selling at Co-Diagnostics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Co-Diagnostics Company Overview

Co-Diagnostics logo
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $1.14
Low: $1.12
High: $1.17

50 Day Range

MA: $1.15
Low: $1.06
High: $1.27

2 Week Range

Now: $1.14
Low: $0.98
High: $1.89

Volume

15,357 shs

Average Volume

64,297 shs

Market Capitalization

$35.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A